Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Immunogenicity and Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine Versus Separate Injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV Administered as Booster Doses to Healthy Children 4-6 Years, Each Co-administered With Merck's MMR Vaccine

NCT00148941 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00148941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00148941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Immunogenicity and Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine Versus Separate Injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV Administered as Booster Doses to Healthy Children 4-6 Years, Each Co-administered With Merck's MMR Vaccine
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
January 6, 2005
Completion date
December 4, 2006
Enrollment
4,209 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, tetanus